That article is simply a hit piece. The article provides absolutely zero to the upside. As if the author knows jack shit about a pharma company. You can pigeon hole umpteen thousand companies to the no revs list. Hasn't stopped the sister with the same tech. However, the article is on point regarding some technicals and longs having lost their shirt. The fact the CEO & CSO is very agressive on the pharmacueticals side of Algernon's coin will hopefully generate some new investors if the marketing strategy works. We certainly cannot rely on potheads pulling us out the gutter, or Dr. Frost (Yost) for that matter.
News 
Market Data 
Discover 
AI
